Exploring trade-offs in diagnostic algorithm, population coverage, and duration of community screening for tuberculosis

Katherine C. Horton[1,2], Alexandra S. Richards[3], Alvaro Schwalb[1,2,4], Rein M. G. J. Houben[1,2]

[1] Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

[2] TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK

[3] School of Health and Wellbeing, University of Glasgow, Glasgow, UK

[4] Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru

Corresponding author: Katherine C. Horton
Keppel Street, London WC1E 7HT, United Kingdom
Phone: +44 20 7636 8636
Email: katherine.horton@lshtm.ac.uk

Abstract

Background

Current tuberculosis (TB) prevention and care strategies have failed to reduce disease burden at the pace required to meet global targets. Community screening may enable more rapid declines in TB burden, but evidence is mixed. We used mathematical modelling to evaluate trade-offs in diagnostic algorithm, population coverage, and duration of screening.

Methods and Findings

Our model recognises symptomatic infectious TB (sTB), asymptomatic infectious TB (aTB), and non-infectious TB (nTB) and was calibrated to infectious TB (sTB+aTB) prevalences of 1,000, 500, and 250 per 100,000 population. We modelled algorithms targeting three disease thresholds: sTB (by prolonged cough with confirmatory GeneXpert Ultra), infectious TB (by GeneXpert Ultra), or all TB (sTB+aTB+nTB, by chest X-ray) with different levels of population coverage and duration. We estimated reductions in sTB incidence and TB mortality up to 10 years after the start of screening.

Maximum coverage (100%) and duration (five rounds) was projected to reduce sTB incidence by 26.9% (22.8-31.5%) with the algorithm targeting sTB and 74.0% (68.5-79.1%) with the algorithm targeting infectious TB for baseline prevalence of 500 per 100,000. However, incidence rebounded at the end of screening, erasing 9.8% and 15.9%, respectively, of those reductions within five years. The algorithm targeting all TB showed higher potential for rapid reductions – over 98% – with negligible rebound if all individuals with nTB were reached; however, low diagnostic accuracy of current tools led to prohibitive overdiagnosis, with 7.2 false positives per true positive in a single round of screening targeting all TB. Screening algorithms targeting lower disease thresholds generally achieved greater impact with lower population coverage and/or duration. Findings were broadly similar for mortality and across baseline prevalences.

Conclusion

Our work highlights opportunities for community screening to achieve the substantial reductions in TB morbidity and mortality required to end TB with approaches that balance diagnostic algorithm, population coverage, and duration of screening.

Manuscript

Introduction

The current global tuberculosis (TB) response relies heavily on passive strategies to diagnosis and treat individuals with TB. Yet TB incidence and mortality have fallen only 8% and 23%, respectively, over the past decade, remaining far above the 2025 EndTB Strategy milestones {World Health Organization, 2015 #54}. In 2023, an estimated 10.8 million people developed tuberculosis (TB), and TB replaced COVID-19 as the leading infectious cause of mortality worldwide [1]. There is growing recognition that passive strategies are insufficient to interrupt transmission at the level required to end TB by 2035 [2].

Community screening offers an opportunity to reach millions who are unable to access TB services [3]. The reach of community screening translated into rapid declines in TB burden in the twentieth century in many countries that now have a low burden of disease [4]. However, the approach was widely discontinued in the 1970s due to cost and logistics, and focus shifted towards strengthening diagnosis and treatment within health systems [5]. Renewed interest in community screening emerged in the 2000s, with the World Health Organization recommending systematic screening in subpopulations with prevalence greater than 1,000 per 100,000 population in 2013 [6] and in subpopulations with prevalence greater than 500 per 100,000 population in 2021 [3]. However, contemporary evidence on the effectiveness of community screening is limited [7, 8], and randomised controlled trials evaluating the impact of systematic screening for TB on disease epidemiology have provided inconsistent support [7].

Inconsistencies in evidence are likely attributable to the vastly different approaches used across studies. Screening approaches must consider a host of factors, including diagnostic algorithm, population coverage, and duration of screening, each of which influences the epidemiological impact of screening. While the optimal approach might combine a highly accurate algorithm targeting a low disease threshold with high population coverage and long duration of screening, maximising all of these factors is rarely feasible due to resource limitations. As such, decisions are required to maximise individual and population health impact whilst minimising demands on financial and human resources.

The relative influence of different screening characteristics is challenging to isolate and compare across randomised controlled trials and other studies. We therefore used mathematical modelling to evaluate the potential epidemiological impact of different community screening approaches for TB, exploring trade-offs in diagnostic algorithm, population coverage, and duration of screening.

Methods

Our analysis considers community screening approaches within a framework that acknowledges a spectrum of disease states including symptomatic infectious TB (sTB, bacteriologically confirmed with report of TB symptoms at screening), asymptomatic infectious TB (aTB, bacteriologically confirmed with no report of TB symptoms at screening), and non-infectious TB (nTB, macroscopic pathology without bacteriological evidence of TB regardless of symptoms) [9, 10]. We focus solely on pulmonary TB in adults and adolescents (age ≥ 15 years).

Model structure and parameterisation

We expanded a compartmental cohort model of *Mycobacterium tuberculosis* (*Mtb*) infection and TB disease (sTB, aTB, and nTB), described elsewhere [9], to incorporate *Mtb* transmission (Figure 1). In our model, susceptible individuals and those who have previously cleared infection are at risk of infection, and individuals who have recovered from nTB are at risk of reinfection (with partial protection [11]), as are those who have been treated for sTB (with increased risk [12]). aTB is considered relatively less infectious than sTB [13]. The model is implemented for a fixed population of 100,000 individuals with susceptible individuals entering the model set equivalent to those exiting to maintain equilibrium. Prior ranges for parameters are presented in Supplemental Table 1 [9, 11-16].

Model calibration

The model was calibrated independently to three levels of infectious TB prevalence: 1,000, 500, and 250 per 100,000 population (± 10%), each after a 300-year run-in period with one-month timesteps to reach a steady state. Calibration was performed in R statistical software [17] using history matching and emulation (hmer) [18] to identify a set of non-implausible parameter values. After achieving a set of parameters consistent with the target prevalence, we used hmer emulators to sample a wider selection of non-implausible points. We then randomly selected 1,000 parameter sets consistent with the target prevalence.

Screening implementation

We examined algorithms designed to target different disease thresholds based on currently available screening and diagnostic tools: sTB by prolonged cough with confirmatory GeneXpert Ultra ("Cough+Xpert"); infectious TB (sTB+aTB) by GeneXpert Ultra ("Xpert"); and all TB (sTB+aTB+nTB) by chest X-ray ("CXR"). The algorithm targeting all TB did not require bacteriological confirmation in order to diagnose individuals with nTB. In scenarios using the algorithm targeting infectious TB, we assumed that 100% of individuals with infectious TB were able to provide an acceptable sample for testing, while only 60% of the remaining population was able to do so. In scenarios using the algorithm targeting sTB, we assumed all those with prolonged cough were able to provide an acceptable sample for testing due to intensified efforts following report of

prolonged cough. Algorithms were defined using probabilities of a positive test result, specific to each model state, which were sampled independently. Probabilities of a positive test were broadly based on sensitivity for sTB and specificity for non-TB states [3, 19-21], complemented by data from national TB prevalence surveys [22, 23], with assumptions where no data were available (Supplemental Table 3 and Supplemental Table 4). For simplicity, we assumed 100% treatment initiation and treatment success among individuals who tested positive for TB.

Community screening was implemented in 12-month rounds. The entire population (adults and adolescents) was eligible for screening over the course of each round of screening, with one-twelfth of the population eligible for screening each month. We considered scenarios with screening coverage ranging from 0% to 100% of the eligible population, distributed proportionally across model states with no increased or decreased likelihood of undergoing screening for those with TB and/or symptoms. We varied duration of screening from one to five consecutive rounds of annual screening with constant population coverage over time for each scenario.

Analysis

For each screening approach, we report the number of individuals with positive screening results for TB, with true positives defined as individuals with sTB, aTB, or nTB, and false positives defined as individuals in any non-TB state. We examined the impact on disease burden by estimating reductions in sTB incidence and TB mortality at the end of screening and ten years after the first year of screening (2035), as well as episodes of sTB and TB-associated deaths averted over the 10-year period from the first year of screening (2025-2035). Results are reported as median values with 95% uncertainty intervals (UIs).

Data accessibility

Replication data and analyses scripts are available on GitHub at https://github.com/ERC-TBornotTB/ScreeningTradeOffs.

Role of the funding source

The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Results

Model calibration

Posterior parameter estimates are presented as median values and 95% credible intervals in Supplemental Table 1. Epidemiological burden estimates for each calibrated model are shown in Supplemental Table 2.

Diagnostic algorithm

The number of individuals with infectious TB reached by the algorithm targeting sTB was less than half the number reached by either the algorithm targeting infectious TB or the algorithm targeting all TB; the algorithm targeting all TB reached significantly more individuals with nTB than either of the other algorithms (Supplemental Table 5). Findings were similar across coverages, durations, and baseline prevalence levels.

However, we estimated that for each individual correctly diagnosed with TB, 2.8 (1.5-4.6), 1.2 (0.9-1.6), and 7.2 (5.5-9.4) individuals without TB tested positive for algorithms targeting sTB, infectious TB, and all TB, respectively, in a single round of screening for a population with baseline prevalence of 500 per 100,000 (Figure 2). The number of false positives per true positive was lower for baseline prevalence of 1,000 per 100,000 and higher for baseline prevalence of 250 per 100,000 (Supplemental Figure 2).

For a single round of screening, the algorithm targeting infectious TB required eight times as many confirmatory tests with GeneXpert Ultra tests as the algorithm targeting sTB across coverage and baseline prevalence levels (Supplemental Figure 3).

Population coverage

For a single round of screening, the number of individuals correctly diagnosed increased proportionally with population coverage across algorithms (Figure *2*). While this linear association would be expected, the effort required to achieve increased coverage would be unlikely to scale linearly. Relative increases were similar for the number of individuals who received false positive results and across baseline prevalence levels.

Duration of screening

At low population coverage (10%), similar numbers of individuals were correctly diagnosed with TB in each round of screening with the algorithm targeting sTB; true positives fell slightly with each round of screening for algorithms targeting lower disease thresholds (Figure 2). In contrast, at maximum coverage (100%), the number of individuals correctly diagnosed in the second round was 20%, 30%, and 60% lower than the first round for the algorithm targeting sTB, the algorithm targeting infectious TB, and the algorithm targeting all TB, respectively. With each subsequent round of screening, the number of true positive results fell, with more substantial declines for algorithms

170 targeting low disease thresholds, reflecting relative impact on disease burden across algorithms. The
171 number of false positives increased slightly (<2% per round) with each subsequent round across
172 population coverage and algorithm. The number of false positives per true positive increased rapidly
173 as high population coverage led to declines in TB prevalence, especially for the algorithm targeting all
174 TB (Figure 2). .

175 *Epidemiological impact*

176 Maximum coverage (100%) and duration (five rounds) with the algorithm targeting sTB resulted in a
177 26.9% (22.8-31.5%) decline in incidence at the end of screening (Figure *3*), which rebounded by 9.8%
178 (7.4-12.9%) within five years. The long-term reduction in incidence 10 years after the start of
179 screening (23.7%, 20.1-28.0%) could also be achieved with the algorithm targeting infectious TB
180 within three rounds with 70% coverage, four rounds with 60% coverage, or five rounds with 50%
181 coverage, or with the algorithm targeting all TB within one round with 60% coverage, two rounds
182 with 40% coverage, three rounds with 30% coverage, or four rounds with 20% coverage (Table 1,
183 orange borders).

184 The algorithm targeting infectious TB, implemented with maximum coverage and duration, resulted
185 in a 74.0% (68.5-79.1%) decline in sTB incidence at the end of screening. Five years later, incidence
186 rebounded by 15.9% (13.5-18.6%) for a 10-year decline of 61.4% (55.4-67.3%). The algorithm
187 targeting all TB could achieve the same long-term reduction in incidence within two rounds of
188 screening with 90% coverage, three rounds with 60% coverage, four rounds with 50% coverage, or
189 five rounds with 40% coverage (Table 1, yellow borders).

190 The algorithm targeting all TB with maximum coverage and duration was projected to reduce
191 incidence by 99.2% (98.8-99.4%) at the end of screening, with negligible rebound (0.1%, 0.1-0.2%),
192 which could not be achieved with other algorithm.

193 Across coverages and durations, the rebound in incidence at the end of screening erased 10-25% of
194 incidence reductions for the algorithm targeting sTB, 16-55% for the algorithm targeting infectious
195 TB, and 0-16% for the algorithm targeting all TB (Supplemental Table 16). Relative epidemiological
196 impact on incidence was similar across baseline prevalence levels.

197 Long-term impact on TB-associated deaths averted and TB mortality ten years after the start of
198 screening was broadly similar to impact on sTB episodes averted and sTB incidence, respectively
199 (Supplemental Table 12, Supplemental Table 13). However, the rebound in mortality at the end of
200 screening was more extreme, erasing 58-87% of mortality reductions for the algorithm targeting sTB,
201 28-72% for the algorithm targeting infectious TB, and 0-25% for the algorithm targeting all TB
202 (Supplemental Table 17).

Discussion

Community screening has the potential to substantially reduce TB morbidity and mortality when implemented with a sufficiently strong balance of diagnostic algorithm, population coverage, and duration of screening. While the same level of epidemiological impact can be achieved through multiple combinations of these factors, screening approaches that target a lower disease threshold generally have higher impact with lower population coverage and/or duration, albeit with higher false positives per true positive.

Our work highlights the importance of symptom-agnostic algorithms, rather than symptom-based algorithms that miss affected individuals who do not report symptoms on screening. Findings from randomized controlled trials of systematic screening support the benefit of a symptom-agnostic approach. Crucially, the ACT3 trial in Viet Nam found that screening adults using GeneXpert annually over a three-year period resulted in a 44% decline in TB prevalence, whereas no impact on prevalence was found in the recent TREATS trial in Zambia and South Africa, in which adults underwent symptom screening before bacteriological testing or other trials with a symptom screen as entry point [7, 24]. While symptom-agnostic screening is likely more expensive than symptom-based screening, the population impact it affords is key for community screening.

Our findings also highlight the potential value of developing an algorithm that can reach beyond infectious TB. We found much greater reductions in disease burden through approaches targeting all TB, including non-infectious disease, which recalls the historical success of mass radiography campaigns [4, 25]. Our results also suggest that treating this reservoir of individuals with early TB enables sustained reduction in disease burden when screening ends. However, our understanding of this disease state is limited. Current tools are not sufficiently capable of distinguishing individuals with non-infectious TB who require treatment from individuals who do not have TB, nor do we understand appropriate treatment regimens for these individuals, nor would we expect high levels of treatment uptake among individuals with no bacteriological evidence of disease. Our modelling approach used a CXR algorithm to illustrate the potential impact of screening approaches that detect individuals across all TB states. However, this standalone approach is not currently a feasible way forward due to the high number of false positives it would generate and the potential harm in placing individuals who do not have TB on treatment [26]. As such, we do not recommend initiating treatment via CXR in community screening. Instead, our results call for the development of diagnostic tools that are sensitive to and treatment regimens that are acceptable for individuals with non-infectious TB.

In our projections of sTB incidence and TB mortality during and after community screening, we observe that both incidence and mortality rebound after each round of screening with algorithms

237 targeting sTB or infectious TB. We believe this is due to the large pool of individuals with non-
238 infectious TB who are not detected in meaningful numbers by bacteriology-focussed approaches and
239 remain in the population while at high risk of progression to infectious TB [27]. This hypothesis is
240 supported by our results from scenarios using the algorithm targeting all TB, which is the only
241 algorithm that does not rely on bacteriological confirmation. Neither incidence nor mortality
242 rebounded meaningfully at the end of screening in these scenarios, and so reductions in burden
243 achieved during screening were sustained afterwards. Further clinical evaluation for individuals with
244 radiographic evidence of TB but negative bacteriological results, and treatment with new, shorter
245 regimens for those with TB-suggestive abnormalities or very high scores computer-aided detection
246 scores, might reduce rebound. These findings could also support a need to consider alternative
247 strategies when screening ends, to ensure reductions in morbidity and mortality are sustained over
248 time.

249 Our work shows the importance of population coverage and duration of screening, with limited
250 impact attributed to single rounds of screening or to multiple rounds of screening with low population
251 coverage, particularly for algorithms targeting a high disease threshold. It is important to note that our
252 work assumes individuals with TB are neither more nor less likely to be screened than other
253 individuals in the population, so population coverage here reflects an equal coverage among
254 individuals with and without TB. If screening reaches a lower proportion of individuals with TB than
255 the proportion of the population that is screened, impact will be reduced [28]. We also recognise that
256 the effort required to achieve true population coverage will not scale linearly, and reaching high levels
257 of population coverage will be difficult in many settings, highlighting the importance of balancing
258 algorithm, coverage, and duration to achieve the desired level of impact with manageable effort.

259 Results presented here are intended to be illustrative. Our analysis focused on a homogeneous
260 population with random mixing and did not incorporate geographic or individual differences in TB-
261 associated risks, social contact patterns, or screening acceptance. Individuals who participate in
262 community screening are unlikely to be evenly distributed across model states, and it is highly
263 unlikely that 100% coverage could be achieved in any setting. However, as our work shows, high
264 coverage is not necessarily needed for substantial impact. Moreover, our work required assumptions
265 about the performance of screening and diagnostic tools across model states where data are not
266 currently available. We were ambitious in our assumptions about production of adequate samples for
267 testing and treatment acceptance among diagnosed individuals, particularly for those without sTB.
268 While we acknowledge limitations, despite attempts to use the best available data, they should not
269 affect the qualitative observations on diagnostic algorithm, population coverage, and duration of
270 screening.

Our use of mathematical modelling allowed us to isolate the impact of different components of community screening approaches and examine a wider array of approaches than would be feasible in randomised controlled trials or community studies. Furthermore, while most community screening programmes assess impact by measuring changes in case notifications, a modelling approach allowed us to quantify impact beyond the individuals directly reached by screening programmes and estimate changes in TB incidence and mortality across the population. Our work highlights opportunities for community screening to achieve the substantial reductions in TB morbidity and mortality required to end TB with approaches that balance diagnostic algorithm, population coverage, and duration.

Funding statement

KCH, ASR, AS, and RMGJH received funding for this work from the European Research Council (ERC) under the European Union's Horizon 2020 Programme (Starting Grant Action Number 757699). KCH is also supported by the UK FCDO (Leaving no-one behind: transforming gendered pathways to health for TB); KCH, AS, and RMGJH by the U.S. National Institutes of Health (R-202309-71190); and ASR by The Wellcome Trust (304666/Z/23/Z).

Authors of this research are partially funded by UK aid from the UK government (to KCH); however the views expressed do not necessarily reflect the UK government's official policies.

Author contributions

KCH: Conceptualisation, Methodology, Software, Formal analysis, Visualisation, Writing - Original Draft. ASR: Conceptualisation, Methodology, Software, Writing - Review & Editing. AS: Methodology, Writing - Review & Editing. RMGJH: Conceptualisation, Methodology, Visualisation, Writing - Review & Editing, Supervision, Funding acquisition.

Competing interests

Authors have no competing interests.

References

1. World Health Organization. Global tuberculosis report 2024. Geneva, Switzerland: World Health Organization, 2024.

2. World Health Organization. The End TB Strategy. Geneva, Switzerland: World Health Organization, 2015.

3. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: screening-systematic screening for tuberculosis disease: World Health Organization; 2021.

301 4. Golub JE, Mohan C, Comstock GW, Chaisson RE. Active case finding of tuberculosis:
302 historical perspective and future prospects. The International Journal of Tuberculosis and Lung
303 Disease. 2005;9(11):1183-203.

304 5. WHO Expert Committee on Tuberculosis. Ninth Report. Technical Report Series no. 552. .
305 Geneva, Switzerland: World Health Organization, 1974.

306 6. World Health Organization. Systematic screening for active tuberculosis: Principles and
307 recommendations. Geneva, Switzerland: World Health Organization, 2013.

308 7. Burke RM, Nliwasa M, Feasey HR, Chaisson LH, Golub JE, Naufal F, et al. Community-
309 based active case-finding interventions for tuberculosis: a systematic review. The Lancet Public
310 Health. 2021;6(5):e283-e99.

311 8. MacPherson P, Shaunabe K, Phiri MD, Rickman HM, Horton KC, Feasey HR, et al.
312 Community-based active-case finding for tuberculosis: navigating a complex minefield. BMC Global
313 Public Health. 2024;2(1):1-14.

314 9. Horton KC, Richards A, Emery JC, Esmail H, Houben RM. Reevaluating progression and
315 pathways following Mycobacterium tuberculosis infection within the spectrum of tuberculosis.
316 Proceedings of the National Academy of Sciences. 2023;120(47):e2221186120.

317 10. Falzon D, Miller C, Law I, Floyd K, Arinaminpathy N, Zignol M, et al. Managing
318 tuberculosis before the onset of symptoms. The Lancet Respiratory Medicine. 2024.

319 11. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of
320 progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clinical
321 Infectious Diseases. 2012;54(6):784-91.

322 12. Verver S, Warren RM, Beyers N, Richardson M, Van Der Spuy GD, Borgdorff MW, et al.
323 Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.
324 American Journal of Respiratory and Critical Care Medicine. 2005;171(12):1430-5.

325 13. Emery JC, Dodd PJ, Banu S, Frascella B, Garden FL, Horton KC, et al. Estimating the
326 contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis
327 from prevalence surveys. Elife. 2023;12:e82469.

328 14. Unted Nations Department of Economic and Social Affairs. World Population Prospects 2022
329 2023. Available from: https://population.un.org/wpp/.

330 15. World Health Organization. Global tuberculosis report 2022. Geneva, Switzerland: World
331 Health Organization, 2022 19 November 2022. Report No.

332 16. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4:
333 treatment-drug-susceptible tuberculosis treatment: World Health Organization; 2022.

334 17. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
335 Foundation for Statistical Computing; 2021.

336 18. Iskauskas A, Vernon I, Goldstein M, Scarponi D, McKinley TJ, White RG, et al. Emulation
337 and History Matching using the hmer Package. arXiv preprint arXiv:220905265. 2022.

338 19. World Health Organization. National tuberculosis prevalence surveys: what diagnostic
339 algorithms should be used in future? Geneva, Switzerland: 2023.

340 20. Kendall EA, Shrestha S, Dowdy DW. The epidemiological importance of subclinical
341 tuberculosis. A critical reappraisal. American Journal of Respiratory and Critical Care Medicine.
342 2021;203(2):168-74.

343 21. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert
344 Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with
345 presumptive pulmonary tuberculosis. Cochrane Database of Systematic Reviews. 2021;(2).

346 22. Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical
347 Tuberculosis Disease—A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden,
348 Associations, and Screening Methodology. Clinical Infectious Diseases. 2021;73(3):e830-e41.

349 23. Mungai B, Ong 'angò J, Ku CC, Henrion MY, Morton B, Joekes E, et al. Accuracy of
350 computer-aided chest X-ray in community-based tuberculosis screening: Lessons from the 2016
351 Kenya National Tuberculosis Prevalence Survey. PLOS Global Public Health. 2022;2(11):e0001272.

352 24. Klinkenberg E, Floyd S, Shanaube K, Mureithi L, Gachie T, de Haas P, et al. Tuberculosis
353 prevalence after 4 years of population-wide systematic TB symptom screening and universal testing
354 and treatment for HIV in the HPTN 071 (PopART) community-randomised trial in Zambia and South
355 Africa: A cross-sectional survey (TREATS). PLoS Medicine. 2023;20(9):e1004278.

356 25. MacPherson P, Stagg HR, Schwalb A, Henderson H, Taylor AE, Burke RM, et al. Impact of
357 active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950–
358 1963: An epidemiological analysis of historical data. PLoS medicine. 2024;21(11):e1004448.

359 26. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS
360 statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical
361 Care Medicine. 2006;174(8):935-52.

362 27. Richards AS, Sossen B, Emery JC, Horton KC, Heinsohn T, Frascella B, et al. Quantifying
363 progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study.
364 Lancet Glob Health. 2023;11(5):E684-E92. doi: 10.1016/S2214-109X(23)00082-7.

365 28. Esmail H, Miller C, Falzon D, de Vries G, Chijioke-Akaniro O, Horton KC, et al. Scaling-up
366 symptom-agnostic, community-wide screening towards global tuberculosis elimination: opportunities,
367 challenges and lessons from history. International Journal of Infectious Diseases. 2025:107875.

368



Figure 1: Model structure. Core model states and transitions are shown in black. All states experience background mortality (not shown). Implementation of community screening approaches is shown in grey, with dashed lines showing pathways onto treatment via screening and dotted lines showing pathways upon treatment completion for treatment via screening.



Figure 2: Number of true positive results, false positive results, and false positive results per true positive result for each round of screening (up to five rounds) by diagnostic algorithm and population coverage. sTB: symptomatic infectious TB; Cough+Xpert: prolonged cough with confirmatory GeneXpert Ultra; Xpert: GeneXpert Ultra; CXR: chest X-ray.



Figure 3: Projected incidence of symptomatic TB (sTB. top) and TB mortality (bottom) for maximum population coverage (100%) and duration of screening (5 years) for diagnostic algorithms targeting sTB (Cough+Xpert), infectious TB (Xpert), and all TB (CXR) in a population with baseline prevalence of 500 per 100,000. Horizontal dashed lines show median reduction at the end of screening for each algorithm. Vertical arrows indicate median rebound in the five years following the end of screening for each algorithm.

Table 1: Projected reductions in symptomatic TB incidence 10 years after the start of screening by diagnostic algorithm, population coverage, and duration in a population with baseline prevalence of 500 per 100,000 population. Orange borders show coverage and duration combinations that could achieve the same impact as maximum coverage and duration with the algorithm targeting symptomatic infectious TB; yellow show coverage and duration combinations that could achieve the same impact as maximum coverage and duration with the algorithm targeting infectious TB.

	Projected reduction in 2035 sTB incidence									
	Population coverage									
Rounds	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%
Algorithm targeting symptomatic infectious TB (Cough+Xpert)										
1	0.6% (0.5-0.7%)	1.2% (0.9-1.4%)	1.7% (1.4-2.1%)	2.3% (1.9-2.8%)	2.9% (2.4-3.6%)	3.5% (2.9-4.3%)	4.1% (3.4-5%)	4.7% (3.8-5.7%)	5.3% (4.3-6.4%)	5.9% (4.8-7.2%)
2	1.2% (0.9-1.4%)	2.3% (1.9-2.8%)	3.4% (2.8-4.1%)	4.5% (3.7-5.5%)	5.6% (4.7-6.7%)	6.6% (5.5-8%)	7.6% (6.3-9.1%)	8.6% (7.2-10.3%)	9.6% (7.9-11.6%)	10.5% (8.7-12.8%)
3	1.7% (1.4-2.1%)	3.4% (2.8-4.2%)	5.1% (4.2-6.1%)	6.6% (5.5-8.1%)	8.2% (6.8-9.8%)	9.6% (8-11.6%)	11% (9.2-13.2%)	12.4% (10.4-15.2%)	13.8% (11.5-16.4%)	15% (12.6-17.9%)
4	2.3% (1.9-2.8%)	4.6% (3.8-5.5%)	6.7% (5.6-8.2%)	8.8% (7.2-10.6%)	10.8% (9-12.9%)	12.6% (10.6-15.1%)	14.4% (12.2-17.2%)	16.1% (13.5-19.4%)	17.8% (15-21.3%)	19.4% (16.2-23%)
5	2.9% (2.4-3.6%)	5.7% (4.7-7%)	8.4% (6.9-10.1%)	10.9% (9.1-13%)	13.3% (11.1-15.9%)	15.5% (13.3-18.5%)	17.7% (15.1-21.1%)	19.9% (16.5-23.7%)	21.8% (18.3-26%)	**23.7% (20.1-28.0%)**
Algorithm targeting infectious TB (Xpert)										
1	1.8% (1.5-2.1%)	3.6% (3-4.2%)	5.5% (4.6-6.4%)	7.3% (6.1-8.4%)	9.2% (7.8-10.6%)	11.1% (9.4-12.8%)	12.9% (11-14.9%)	14.8% (12.4-17.4%)	16.7% (14.1-19.6%)	18.6% (15.8-21.8%)
2	3.6% (3.1-4.2%)	7.1% (6.1-8.2%)	10.6% (9-12.3%)	13.9% (11.9-16.2%)	17.2% (14.8-19.9%)	20.3% (17.5-23.5%)	23.4% (20.1-27%)	26.4% (22.6-30.1%)	29.3% (25.2-33.7%)	32% (27.7-36.5%)
3	5.4% (4.6-6.3%)	10.5% (9-12.3%)	15.5% (13.3-17.9%)	20.3% (17.3-23.1%)	24.6% (21.2-28.3%)	28.9% (25-32.7%)	**32.9% (28.6-37.1%)**	36.6% (31.6-41.5%)	40.2% (34.6-45.5%)	43.3% (37.8-48.9%)
4	7.2% (6.1-8.3%)	13.9% (12-16%)	20.2% (17.4-23.2%)	26.1% (22.5-29.8%)	31.5% (27.2-35.8%)	**36.6% (31.9-41.6%)**	41.3% (36.5-46.4%)	45.5% (39.6-51%)	49.6% (44-55.2%)	53.4% (47.3-58.8%)
5	9% (7.6-10.4%)	17.2% (14.9-19.8%)	24.8% (21.3-28.5%)	31.7% (27.5-35.8%)	**37.9% (33.2-42.8%)**	43.6% (38.5-48.9%)	48.7% (42.8-54.5%)	53.3% (47.4-59.2%)	57.5% (51.6-63.3%)	**61.4% (55.4-67.3%)**
Algorithm targeting all TB (CXR)										
1	5.2% (4.8-5.5%)	10.5% (9.8-11.2%)	15.9% (14.8-17%)	21.4% (20-22.8%)	26.9% (25-28.8%)	**32.7% (30.5-34.8%)**	38.6% (35.9-41%)	44.4% (41.6-47.4%)	50.6% (47.3-54%)	56.8% (53.2-60.6%)
2	10.3% (9.5-10.9%)	20.2% (18.8-21.4%)	29.7% (27.9-31.5%)	**38.8% (36.4-41.2%)**	47.6% (44.7-50.1%)	55.6% (52.5-58.4%)	63.2% (60.1-66.3%)	70.3% (66.8-73.3%)	**76.8% (73.3-79.6%)**	82.5% (79.1-85.4%)
3	15.1% (14.2-16.1%)	29% (27.3-30.8%)	**41.7% (39.3-43.8%)**	52.9% (50.2-55.4%)	62.7% (59.9-65.5%)	**71.4% (68.5-74.1%)**	78.6% (75.7-81.0%)	84.6% (81.9-86.9%)	89.4% (87-91.4%)	93.1% (91.0-94.8%)
4	19.9% (18.6-21.1%)	**37.2% (35.1-39.1%)**	51.8% (49.3-54.3%)	64% (61.2-66.7%)	**73.8% (71.3-76.4%)**	81.7% (79.1-84%)	87.7% (85.4-89.7%)	92.2% (90.3-93.7%)	95.3% (93.8-96.5%)	97.4% (96.4-98.2%)
5	24.5% (23.1-25.9%)	44.6% (42.1-46.6%)	60.4% (57.7-62.8%)	**72.7% (69.8-75.2%)**	81.9% (79.5-84.1%)	88.5% (86.4-90.2%)	93.1% (91.4-94.5%)	96.1% (94.9-97%)	97.9% (97.1-98.6%)	99% (98.5-99.4%)